Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Blinded, Placebo-controlled Study to Assess Pharmacokinetics, Safety, and Tolerability of Ascending Doses of MEDI0382 in Non-diabetic Obese Subjects

Trial Profile

A Randomized, Blinded, Placebo-controlled Study to Assess Pharmacokinetics, Safety, and Tolerability of Ascending Doses of MEDI0382 in Non-diabetic Obese Subjects

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 08 Nov 2018

At a glance

  • Drugs MEDI 0382 (Primary)
  • Indications Obesity
  • Focus Adverse reactions
  • Sponsors MedImmune
  • Most Recent Events

    • 02 Oct 2018 Status changed from recruiting to active, no longer recruiting.
    • 05 Sep 2018 Planned End Date changed from 25 Dec 2018 to 11 Dec 2018.
    • 05 Sep 2018 Planned primary completion date changed from 25 Dec 2018 to 11 Dec 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top